CME

In early 2012, the ADA and the EASD issued a joint position statement emphasizing patient specific treatment of hyperglycemia for T2DM. The impetus underlying the new guidelines was the growing appreciation of the complexity surrounding contemporary glycemic management in patients with T2DM. Notwithstanding, the ability of many physicians to adequately select and intensify T2DM treatment regimens has been historically poor, suffering from lack of confidence in managing complex combinations of agents across myriad patient demographics and comorbid conditions. SGLT-2 inhibitors are an emerging class of drug which have been added to this armamentarium. 0.5 CME Credits

Please join our expert faculty for discussion on the latest findings on melanoma management, including clinically important breakthroughs in genetics and genomics and the impact of newly emergent therapies on optimizing patient outcomes in metastatic melanoma. 0.5 CME Credits

Initial identification and maintenance of remission are critical issues within the treatment and management of therapy for patients with ulcerative colitis. Dr. Asher Kornbluth will highlight these issues through a case-based discussion. Key points will include disease classification, the role of topical therapy, and dose adjustments. 0.25 CME Credits

Hypoactive sexual desire disorder (HSDD) is the most common female sexual dysfunction, with about 10% of premenopausal women in the U.S. believed to have this condition. HSDD is consistently under-diagnosed and under-managed, due in great measure to the lack of adequate physician-patient communication on this topic. This CME interview will discuss the symptoms of HSDD and its impact on a patient's quality of life, along with the components for a comprehensive sexual history. It will also discuss causal factors for HSDD and common comorbid conditions, as well as therapeutic modalities available to manage HSDD, including their benefits and potential side effects.

CME credits: 0.50 Valid until: 12/04/2014 Claim your CME credit at http://www.reachmd.com/cmedetails.aspx?sid=6822Please join our expert faculty for discussion on the latest findings on melanoma management, including clinically important breakthroughs in genetics and genomics and the impact of newly emergent therapies on optimizing patient outcomes in metastatic melanoma.

CME credits: 0.50 Valid until: 12/04/2014 Claim your CME credit at http://www.reachmd.com/cmedetails.aspx?sid=6861In early 2012, the ADA and the EASD issued a joint position statement emphasizing patient specific treatment of hyperglycemia for T2DM. The impetus underlying the new guidelines was the growing appreciation of the complexity surrounding contemporary glycemic management in patients with T2DM. Notwithstanding, the ability of many physicians to adequately select and intensify T2DM treatment regimens has been historically poor, suffering from lack of confidence in managing complex combinations of agents across myriad patient demographics and comorbid conditions. SGLT-2 inhibitors are an emerging class of drug which have been added to this armamentarium. On January 8, 2014, after launch of this CME activity, FDA approved the SGLT-2 inhibitor dapagliflozin for the treatment of patients with type 2 diabetes. On September 19, 2014 an another drug received FDA approval of Trulicity to also treat type 2 diabetes. Canagliflozin, the first approved SGLT-2 inhibitor for the treatment of patients with type 2 diabetes, was approved by FDA on March 29, 2013. Estimated time to complete activity: 30 minutesAfter you have complete this activity, click below to participate in the second part of this series: Part 1 with Vivian Fonseca, MD

CME credits: 0.25 Valid until: 12/03/2014 Claim your CME credit at http://www.reachmd.com/cmedetails.aspx?sid=6859Initial identification and maintenance of remission are critical issues within the treatment and management of therapy for patients with ulcerative colitis. Dr. Asher Kornbluth will highlight these issues through a case-based discussion. Key points will include disease classification, the role of topical therapy, and dose adjustments. Estimated time to complete activity: 15 minutes

CME credits: 0.50 Valid until: 11/26/2014 Claim your CME credit at http://www.reachmd.com/cmedetails.aspx?sid=6860In early 2012, the ADA and the EASD issued a joint position statement emphasizing patient specific treatment of hyperglycemia for T2DM. The impetus underlying the new guidelines was the growing appreciation of the complexity surrounding contemporary glycemic management in patients with T2DM. Factors complicating management include the increasing number and variety of available pharmacotherapy agents, potential adverse effects, and new uncertainties concerning the effects of intensive glycemic control on macrovascular complications.Notwithstanding, the ability of many physicians to adequately select and intensify T2DM treatment regimens has been historically poor, suffering from lack of confidence in managing complex combinations of agents across myriad patient demographics and comorbid conditions. SGLT-2 inhibitors are among the emerging therapeutic classes for managing T2DM and have a number of interesting properties. On January 8, 2014, after launch of this CME activity, FDA approved the SGLT-2 inhibitor dapagliflozin for the treatment of patients with type 2 diabetes. On September 19, 2014 an another drug received FDA approval of Trulicity to also treat type 2 diabetes. Canagliflozin, the first approved SGLT-2 inhibitor for the treatment of patients with type 2 diabetes, was approved by FDA on March 29, 2013. Estimated time to complete activity: 30 minutes After you have complete this activity, click below to participate in the second part of this series: Part 2 with Vivian Fonseca, MD

Host: Prathima Setty, MD Fertility preservation technologies have become more advanced and more accessible over the past several years. Joining host Dr. Prathima Setty to discuss current options for women to protect their fertility is Dr. Naveed Khan, Reproductive Endocrinology and Infertility Specialist in Leesburg, VA. Dr. Khan practices with Shady Grove Fertility, the nation's largest fertility center, and is also a member of the American College of Obstetrics and Gynecology and the American Society of Reproductive Medicine.

Host: Prathima Setty, MD Fertility preservation technologies have become more advanced and more accessible over the past several years. Joining host Dr. Prathima Setty to discuss current options for women to protect their fertility is Dr. Naveed Khan, Reproductive Endocrinology and Infertility Specialist in Leesburg, VA. Dr. Khan practices with Shady Grove Fertility, the nation's largest fertility center, and is also a member of the American College of Obstetrics and Gynecology and the American Society of Reproductive Medicine.

CME credits: 0.50 Valid until: 12/31/2014 Claim your CME credit at http://www.reachmd.com/cmedetails.aspx?sid=6857Noninvasive prenatal screening utilizing DNA technology offers tremendous potential as a screening tool for fetal aneuploidy. Both ACOG and ACMG have recently published guidelines surrounding the use of NIPS. Please join Dr. Susan Gross as she explains the benefits and limitations of NIPS and diagnostic testing options. Estimated time to complete activity: 30 minutes

Noninvasive prenatal screening utilizing DNA technology offers tremendous potential as a screening tool for fetal aneuploidy. Both ACOG and ACMG have recently published guidelines surrounding the use of NIPS. Please join Dr. Susan Gross as she explains the benefits and limitations of NIPS and diagnostic testing options. 0.5 CME Credits

Noninvasive prenatal screening utilizing DNA technology offers tremendous potential as a screening tool for fetal aneuploidy. Both ACOG and ACMG have recently published guidelines surrounding the use of NIPS. Please join Dr. Susan Gross as she explains the benefits and limitations of NIPS and diagnostic testing options. 0.5 CME Credits

Melanoma is the most aggressive form of skin cancer and its incidence continues to increase dramatically. It is likely that more than 76,000 new cases will be diagnosed in the US in 2014. New therapeutic approaches are being aggressively sought that will positively impact patient quality of life and survival. Join us as Dr. John Kirkwood addresses how to sequence immunotherapies and targeted therapies to treat patients with melanoma. As of September 4, 2014, the FDA approved Pembrolizumab (Keytruda). This drug won FDA approval for treating advanced or unresectable melanoma in patients not responding to other therapies. This interview may include discussion on this drug or drugs in a related drug class. Please note this updated approval while participating in this activity. To learn more visit: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm412802.htm

Hyponatremia is the most commonly encountered electrolyte disturbance seen in hospitalized patients, and occurs as a result of a variety of clinical conditions. Please join our three panelists, Drs. Hauptman, Janicic and Zacks, as each discusses hyponatremia in reference to their patients with heart failure, syndrome of inappropriate antidiuretic hormone (SIADH), or cirrhosis, respectively. Issues relating to diagnosis, treatment, and potential complications will be discussed. 0.5 CME Credits